Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Maria Goleba

Internal Medicine Davison, MI Medical Doctor

NPI 1306834429 CMS profile 104221

10080 E Lippincott Blvd, Davison, MI 48423

Open in the dashboard

General payments

$6,721

357 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Maria Goleba of Davison, MI is reported in the CMS Open Payments database as having received $6,721 across 357 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $233 12
2024 General $1,302 68
2023 General $1,894 117
2022 General $1,876 76
2021 General $149 6
2020 General $346 23
2019 General $921 55

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Maria Goleba
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Maria Goleba were reported at $233. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Maria Goleba Internal Medicine median Middle half National median
2019 $921 $159 $48–$570 $163
2020 $346 $119 $33–$402 $114
2021 $149 $135 $37–$521 $132
2022 $1,876 $141 $42–$496 $149
2023 $1,894 $149 $45–$519 $160
2024 $1,302 $154 $47–$537 $164
2025 $233 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,579 67 payments
  2. AstraZeneca Pharmaceuticals LP $1,013 56 payments
  3. Novo Nordisk Inc $519 32 payments
  4. Amgen Inc. $396 22 payments
  5. Pfizer Inc. $372 23 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $340 19 payments
  7. Novartis Pharmaceuticals Corporation $188 10 payments
  8. Lilly USA, LLC $173 12 payments
  9. Astellas Pharma US Inc $155 9 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $143 7 payments
  11. Other $1,844 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,829 352 payments
  2. Travel and Lodging $614 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $250 2 payments
  4. Education $28 2 payments
Products named General payments · program years 2019–2025
  1. UBRELVY $1,046 30 payments
  2. BREZTRI $527 23 payments
  3. QULIPTA $444 38 payments
  4. Ozempic $380 23 payments
  5. RYBELSUS $349 21 payments
  6. FARXIGA $323 15 payments
  7. Repatha $295 16 payments
  8. PAXLOVID $259 15 payments
  9. NURTEC ODT $228 13 payments
  10. ELIQUIS $198 11 payments
  11. Other $4,883 279 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 217 drugs

Part D claims

20,727

Median for Internal Medicine: 777

Drug cost

$1,625,197

Median for Internal Medicine: $73,373

Branded share of claims

22%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 275 $324,758
Eliquis Apixaban Brand 215 $241,703
Trulicity Dulaglutide Brand 131 $132,646
Januvia Sitagliptin Phosphate Brand 75 $105,371
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 117 $87,958
Jardiance Empagliflozin Brand 55 $56,775
Xarelto Rivaroxaban Brand 53 $52,921
Rybelsus Semaglutide Brand 19 $33,482
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 196 $31,827
Tradjenta Linagliptin Brand 26 $24,531

The 10 drugs with the highest cost, of 217 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$47,857

Medicare's payments for the services billed

Medicare patients

344

Average age 71

Services billed

807

253 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 39%
Diabetes 28%
COPD 20%
Chronic kidney disease 19%
Ischemic heart disease 18%
Depression 17%
Heart failure 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 26 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BREZTRI
  • AstraZeneca Pharmaceuticals LP $132
$132 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $108
$108 — —
UBRELVY
  • AbbVie, Inc. $88
$88 — —
QULIPTA
  • AbbVie, Inc. $88
$88 — —
Veozah
  • Astellas Pharma US Inc $87
$87 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 26 with Patron

Records

357 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record